{"id":"W4292641407","doi":"10.1038/s41591-022-01933-w","title":"Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial","year":2022,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"ca_institutions":"William Osler Health System; University of Toronto","funders":"Sanofi Genzyme; EMD Serono; AstraZeneca; Genentech; Amgen; Tizona Therapeutics; Chinese Society of Clinical Oncology; Astellas Pharma; Y-mAbs Therapeutics; Eisai; G1 Therapeutics; Lunit; Puma Biotechnology; Relay Therapeutics; Yuhan; Loxo Oncology; Ribon Therapeutics; Syndax Pharmaceuticals; BeiGene; Hong Kong Cancer Fund; Jounce Therapeutics; Regeneron Pharmaceuticals; Helsinn; Mirati Therapeutics; Mylan; Daiichi Sankyo Europe; Takeda Oncology; Foundation Medicine; GlaxoSmithKline; Vertex Pharmaceuticals; Array BioPharma; Gilead Sciences; Taiho Pharmaceutical; Merck KGaA; LEO Pharma; Eli Lilly and Company; Calithera Biosciences; AbbVie; Revolution Medicines; Exelixis; Sanofi; National Cancer Institute; Grifols; F. Hoffmann-La Roche; Roche; PharmaMar; OncoMed Pharmaceutical; Incyte; Pfizer; Bristol-Myers Squibb","keywords":"Atezolizumab; Medicine; Oncology; Internal medicine; Hazard ratio; Lung cancer; Clinical endpoint; Population; Cohort; Biomarker; Randomized controlled trial; Confidence interval; Cancer; Pembrolizumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001526755,0.0003202368,0.00214603,0.001058676,0.00008423266,0.000005022971,0.0001824082,0.00008325292,0.003870038],"category_scores_gemma":[0.0003776081,0.0001986654,0.0003313874,0.003061089,0.0004045482,0.00005193361,0.00001785854,0.0006968364,3.677346e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003203518,"about_ca_system_score_gemma":0.000807155,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003492181,"about_ca_topic_score_gemma":0.00007663367,"domain_scores_codex":[0.9965953,0.0003358727,0.0009072738,0.0004736873,0.001401878,0.0002859852],"domain_scores_gemma":[0.9975653,0.001197253,0.0005370946,0.0004043776,0.0001906719,0.0001053257],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9777732,0.001149711,0.00009313707,0.00009921505,0.008269662,0.0004730878,0.0003777956,0.0006488147,0.007054079,0.00003091428,0.0001875998,0.00384281],"study_design_scores_gemma":[0.974829,0.009136858,0.00141321,0.0001587043,0.009456377,0.00004712689,0.0004148005,0.001318465,0.001874349,0.000008533623,0.001127005,0.0002155972],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9884691,0.002887856,0.0001545481,0.004410202,0.000549089,0.003069326,0.0001192026,0.00004378955,0.0002969229],"genre_scores_gemma":[0.9929817,0.000103414,0.001283056,0.003010628,0.0002101687,0.0005720021,0.001529505,0.00004148377,0.0002680267],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007987147,"threshold_uncertainty_score":0.9970406,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01030460958035551,"score_gpt":0.3133534069105685,"score_spread":0.303048797330213,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}